The Biomarkers Consortium brings together various partners to identify, develop and qualify potential biomarkers to improve drug development and regulatory decision-making.
SpotlightSkip This Section
A new Biomarkers Consortium project will validate an imaging tool that could be a catalyst in developing effective treatments for Alzheimer’s disease.
A new publication from the Plasma Aβ Project shows that some blood-based tests could be the first step in screening for Alzheimer’s disease.
The FDA approves FNIH biomarker qualification plan for the first surrogate endpoint in osteoporosis clinical trials
The FNIH Biomarkers Consortium launches a project to detect the earliest changes in rare neurodegenerative diseases.
The FNIH Biomarkers Consortium launches a project to investigate new methods of detecting measurable residual disease in patients with acute myeloid leukemia.
Improving health through meaningful measurements.
To create and lead cross-sector efforts that validate and qualify biomarkers and other drug development tools to accelerate better decision making for the development of new therapeutics and health technologies.